Pathology of radiation and anthracycline cardiotoxicity

Pediatric Blood and Cancer

Volumn 44, Issue 7, 2005, Pages 630-637

  Berry, Gerald J ^a   Jorden, Michelle ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracycline cardiac pathology; Coronary artery disease; Radiation cardiac pathology; Radiation valvular disease

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; DAUNORUBICIN; DOXORUBICIN; LIPOSOMAL DAUNORUBICIN; LIPOSOME; MACROGOL; UNCLASSIFIED DRUG;

ACUTE RADIATION PERICARDITIS SYNDROME; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILD HEALTH; CHILDHOOD CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONSTRICTIVE PERICARDITIS; CORONARY ARTERY; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; ECHOCARDIOGRAPHY; ENDOCARDIUM; HEALTH HAZARD; HEART DISEASE; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART VALVE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; PATHOGENESIS; PERICARDIECTOMY; PERICARDIOCENTESIS; PERICARDITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION INDUCED HEART DISEASE; RADIATION INDUCED VASCULOPATHY; RADIATION INJURY; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL RATE; VASCULAR DISEASE;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; HEART; HUMANS; NEOPLASMS; RADIATION INJURIES; SURVIVORS;

EID: 18244374993     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20346     Document Type: Conference Paper

References (45)

1. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology. Task force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-842.
2. Stewart JR, Fajardo LF, Gillette SM, et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995;31:1205-1211.
3. Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999;93:761-779.
4. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment for Hodgkin's disease. J Am Med Assoc 1993;270:1949-1955.
5. Gyenes G. Radiation-induced ischemic heart disease in breast cancer - A review. Acta Oncol 1998;37:241-246.
6. Paszat LF, Mackillop WJ, Groome PA, et al. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol 1998;16:2625-2631.
7. Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer 1976;37:2813-2825.
8. Pohjola-Sintonen S, Totterman KJ, Salmo M, et al. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease. Cancer 1987;60:31-37.
9. Perrault DJ, Levy M, Herman JD, et al. Echocardiographic abnormalities following cardiac irradiation. J Clin Oncol 1985;3: 546-551.
10. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003; 45:55-75.
11. Virmani R, Burke A, Farb A, et al., editors. Cardiovascular pathology. Philadelphia: W.B. Saunders Co; 2001. p 541.
12. Smith AL, Book WM. Effect of noncardiac drugs, electricity, poisons, and radiation on the heart. In: Fuster V, Alexander RW, O'Rourke RA, et al., editors. Hurst's the heart. New York: McGraw-Hill; 2004. pp 2155-2168.
13. Fajardo LF, Berthrong M, Anderson RE, editors. Radiation pathology. New York: Oxford University Press, Inc; 2001. p 454.
14. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: A surgical and autopsy study of 27 cases. Hum Pathol 1996;27:766-773.
15. Brosius FC, Waller BF, Roberts WC. Radiation heart disease: Analysis of 16 young (aged 15-33 years) necropsy patients ho received over 3500 rads to the heart. Am J Med 1981;70:519-530.
16. Mittal S, Berko B, Bavaria J, et al. Radiation-induced cardiovascular dysfunction. Am J Cardiol 1996;78:114-115.
17. Carlson RG, Mayfield WR, Normann S, et al. Radiation-associated valvular disease. Chest 1991;99:538-545.
18. Arsenian MA. Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis 1991;33:299-312.
19. Basavaraju SR. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 2002;29:2391-2403.
20. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993;7:1208-1215.
21. Om A, Ellahham S, Vetrovec GW. Radiation-induced coronary artery disease. Am Heart J 1992;124:1598-1602.
22. Amronin GD, Gildenhorn HL, Solomon ED, et al. The synergism of x-irradiation and cholesterol-fat feeding on the development of coronary artery lesions. J Atheroscler Res 1964;4:325-334.
23. Bradley EW, Zook BC, Casarett GW, et al. Coronary arteriosclerosis and atherosclerosis in fast neutron or photon irradiated dogs. Int J Radiat Oncol Biol Phys 1981;7:1103-1108.
24. Fajardo LF, Lee A. Rupture of major vessels after radiation. Cancer 1976;36:904-913.
25. Lefrak EA, Pitha J, Rosenheim S, et al. A Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
26. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-2879.
27. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:72-85.
28. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. NEJM 1998;339:900-905.
29. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Safety 2000;22:263-302.
30. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Int Med 1996;125:47-55.
31. Bristow MR, Thompson PD, Martin PR, et al. Early anthracycline cardiotoxicity. Am J Med 1978;65:823-828.
32. Harrison DT, Sanders LA. Pericarditis in a case of early daunorubicin cardiomyopathy. Ann Int Med 1976;85:339-340.
33. Billingham ME, Mason JW, Bristow MR, et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-873.
34. Billingham ME. Endomyocardial changes in anthracycline-treated patients with and without irradiation. Front Radiat Ther Onc 1979;13:67-81.
35. Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: Predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Sympos 1984;3:71-76.
36. Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Gen Metab 2000;71:436-444.
37. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
38. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003;8:17-24.
39. Berry GJ, Billingham ME, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711-716.
40. 2. Ann Oncol 2000;11: 1029-1033.
41. Mlineritsch B, Mayer P, Moik M, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx)-monotherapy in previous treated metastatic breast cancer. Breast Cancer Res Treat 2001;69: 287.
42. 2 of liposomal doxorubicin. Lancet Oncol 2004;9:575-577.
43. Lowis S, Lewis I, Elsworth A, et al. Cardiac toxicity may limit the usefulness of liposomal daunorubicin (DaunoXome): Results of a phase I study in children with relapsed or resistant tumours - A UKCCSG/SFOP study (abstract 435). Proc Am Soc Clin Oncol 2002;21:109A.
44. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 2004;100:2052-2063.
45. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: A prospective longitudinal study. Cancer 2003;97:1991-1998.